Defining meaningful change in Alzheimer's disease trials: The donepezil experience

Journal of Geriatric Psychiatry and Neurology

Volumn 12, Issue 1, 1999, Pages 39-48

  McLendon, Beth M ^a   Doraiswamy, Murali P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL;

ALZHEIMER DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DRUG EFFICACY; EUROPE; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RATING SCALE; REVIEW; UNITED STATES;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; GUIDELINES; HUMANS; INDANS; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0032793305     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/089198879901200108     Document Type: Review

References (46)

1. Gracon S, Smith F, Hoover T, et al. Long-term tacrine treatment: effect on nursing home placement and mortality. In: Becker R, Giacobini E, eds. Alzheimer disease: from molecular biology to therapy. Boston: Birkhaüser, 1996:205-209.
2. Knopman DS, Schneider L, Davis K, et al. Long-term tacrine (Cognex™) treatment: effects on nursing home placement and mortality. Neurology 1996; 47:166-177.
3. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegeline, alpha-tocopheral or both as treatment for Alzheimer's disease. N Engl J Med 1997; 336:1216-1222.
4. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin Ther 1998; 20:838-850.
5. Thal LJ. Clinical testing of new drugs for efficacy in Alzheimer's disease. In: Giacobini E, Becker R, eds. Alzheimer disease: therapeutic strategies. Boston: Birkhaüser, 1994:436-440.
6. Ferris SH, Lucca U, Mohs R, et al. Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997; 11(suppl 3):34-38.
7. Reisberg B, Schneider L, Doody R, et al. Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of dementia drug guidelines. Alzheimer Dis Assoc Disord 1997; 11(suppl 3):8-18.
8. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S22-S32.
9. Leber P. Guidelines for the clinical evaluation of antidementia drugs. First draft. Rockville, MD: US Food and Drug Administration, 1990.
10. Leber P. FDA letter to sponsors recommending use of CIBIC in dementia trials. Rockville, MD: US Food and Drug Administration, 1990.
11. Galasko D, Hansen L, Katzman R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994; 51:888-895.
12. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
13. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114:797-811.
14. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part 1: clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989; 39:1159-1165.
15. Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 1983; 19:448-450.
16. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141:1456-1464.
17. Doraiswamy PM, Bieber F, Kaiser L, et al. The Alzheimer's disease assessment scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology 1997; 48:1511-1517.
18. Zec RF, Landreth ES, Vicari SK, et al. Alzheimer disease assessment scale: useful for both early detection and staging of dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 1992; 6:89-102.
19. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate and predictors of cognitive deterioration. Am J Psychiatry 1994; 151:390-396.
20. Kramer-Ginsberg E, Mohs RC, Aryan M, et al. Clinical predictors of the course of Alzheimer's disease patients in a longitudinal study: a preliminary report. Psychopharmacol Bull 1988; 24:458-462.
21. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327:1253-1259.
22. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271:985-991.
23. Thal LJ, Schwartz G, Sano M, et al. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology 1996; 47:1389-1395.
24. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer's disease. A 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158:1021-1031.
25. Rogers SL, Farlow MR, Mohs R, et al. A 24-week double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50:136-145.
26. Corey-Bloom J, Anand R, Veach J, et al. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1:55-65.
27. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998; 50:1222-1230.
28. Friedhoff LT, Ieni JR, Rogers SL, Pratt RD. Donepezil provides long-term clinical benefits for patients with Alzheimer's disease. Abstract presented at the XXIst CINP Congress, July 12-16, 1998, Glasgow, UK.
29. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicenter open label extension study. Eur Neuropsychopharmacol 1998; 8(1):67-75.
30. Rogers SL, Friedhoff LT. Donepezil provides long-term clinical benefits for patients with Alzheimer's disease (AD). J Neurol Sci 1997; 150(suppl):S296(5-12-21).
31. Rogers SL, Friedhoff LT, Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dement Geriatr Cogn Disord 1996; 7:293-303.
32. Doody R, Clark C, Farlow M, et al. Chronic donepezil treatment is associated with slowed cognitive decline. Neurobiol Aging 1998; 19(4S):S303.
33. Solomon PR, Knapp MJ, Gracon SI, et al. Long-term tacrine treatment in patients with Alzheimer's disease. Lancet 1996; 348:275-276.
34. Schneider LS, Olin JT. Quantitative overview of the efficacy of Hydergine. Arch Neurol 1994; 51:787-798.
35. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140:566-572.
36. Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for the assessment of primary degenerative dementia. Am J Psychiatry 1982; 139:1136-1139.
37. Reisberg B. Functional Assessment Staging (FAST). Psychopharmacol Bull 1988; 24:653-659.
38. Knopman DS, Knapp DJ, Gracon SI, et al. The clinician's interview-based impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994; 44:2315-2321.
39. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10:237-244.
40. Berg L, Miller JP, Baty J, et al. Mild senile dementia of the Alzheimer type 4. Evaluation of intervention. Ann Neurol 1992; 31:242-249.
41. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268:2523-2529.
42. Doody RS, Pratt RD, Perdomo CA. Clinical benefits of donepezil: results from a long-term phase III extension trial. Neurology 1999; 52(suppl 2):A174.
43. Mohs RC, Marin D, Green CR, Davis KL. The Alzheimer's Disease Assessment Scale: modifications that can enhance its use in future clinical trials. In: Becker R, Giacobini E, eds, Alzheimer disease: from molecular biology to therapy. Boston: Birkhaüser, 1996:407-411.
44. Mohs RC, Knopman D, Peterson RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S13-S21.
45. Zec RF, Landreth ES, Bird E, et al. Psychometric strengths and weaknesses of the Alzheimer Disease Assessment Scale in clinical testing: recommendations for improvements. In: Giacobini E, Becker R, eds. Alzheimer disease: therapeutic strategies. Boston: Birkhaüser, 1994:444-449.
46. Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S51-S56.